DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic StrokeBusiness Wire • 13 days ago
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today announced the...
Share to Feed
Related Stocks: NAS:DMAC...
DiaMedica Therapeutics (NASDAQ:DMAC Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.14) earnings per share for the quarter, meeting analysts’...
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a...
This price move could indicate a change in the trend, and may be a buy signal for investors...
This price move could be a signal that DMAC may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options...
This is a Bullish indicator signaling DMAC's price could rise from here. Traders may explore going long the stock or buying call options...
This indicator may be signaling DMAC's price has momentum to move higher, since its current price moved above its price 14 days ago. Traders may consider buying the stock or exploring call options...
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke (AIS), today...
DiaMedica Therapeutics names Masuoka as its chief medical officer...